Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, Giovanna Esposito, Claudio Dazzi, Luigi Cavanna, Marco Angelo Burgio, Francesco Rosetti, Simona Rizzato, Floriana Morgillo, Saverio Cinieri, Antonello Veccia, Maximilan Papi, Giuseppe Tonini, Vittorio Gebbia, Serena Ricciardi, Daniele Pozzessere, Alessandra Ferro, Claudia Proto, Raffaele Costanzo, Manolo D’Arcangelo, Manuela Proietto, Piera Gargiulo, Raimondo Di Liello, Laura Arenare, Filippo De Marinis, Lucio Crinò, Fortunato Ciardiello, Nicola Normanno, Ciro Gallo, Francesco Perrone, Cesare Gridelli, Alessandro Morabito
Publikováno v:
Journal of Thoracic Oncology. 17:1086-1097
Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available in non-Asian patients. BEVERLY is an Italian, multicenter, randomize
Publikováno v:
The Thoracic and Cardiovascular Surgeon. 70:273-276
This case series aimed to analyze the outcomes of patients referred for salvage pulmonary resections after treatment with chemotherapy and immunotherapy for previously metastatic or unresectable tumors.From October 2016, after multidisciplinary board
Autor:
Yi-Long Wu, Ying Cheng, Jianying Zhou, Shun Lu, Yiping Zhang, Jun Zhao, Dong-Wan Kim, Ross Andrew Soo, Sang-We Kim, Hongming Pan, Yuh-Min Chen, Chih-Feng Chian, Xiaoqing Liu, Daniel Shao Weng Tan, Rolf Bruns, Josef Straub, Andreas Johne, Jürgen Scheele, Keunchil Park, James Chih-Hsin Yang, Zhe Liu, Xi Chen, Mengzhao Wang, Shiying Yu, Helong Zhang, Jian Fang, Wei Li, Chih-Hsin Yang, Gee-Chen Chang, Te-Chun Hsia, Cheng-Ta Yang, Chin-Chou Wang, Byoung Chul Cho, Ki Hyeong Lee, Young-Chul Kim, Ho Jung An, In Sook Woo, Jae Yong Cho, Sang Won Shin, Jong-Seok Lee, Joo-Hang Kim, Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Shao Weng Daniel Tan, Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles Blanco, Martin Emilio Lazaro Quintela, Enriqueta Felip Font, Anne-Marie Dingemans, Lynne Bui
Publikováno v:
The Lancet Respiratory Medicine. 8:1132-1143
Summary Background We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexp
Autor:
Roy S. Herbst, Hiroshi Kuriki, Young-Chul Kim, See Phan, Giuseppe Giaccone, Filippo de Marinis, Carlos H. Barrios, David R. Spigel, Kimberly Komatsubara, Enriqueta Felip, Mark McCleland, Simonetta Mocci, Ida Berglin Enquist, Masahiro Morise, Cristina Oprean, Jacek Jassem, Z. Andric, Monette Villalobos, A. Vergnenegre
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(11)
Introduction IMpower110 previously revealed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR- and ALK-negative (wild type [WT]) metastatic NSCLC with high programmed death-ligand 1
Autor:
J. Goldschmidt, Keunchil Park, Filippo de Marinis, M. Gandhi, Paul Conkling, Achim Rittmeyer, Rimas V. Lukas, Joachim von Pawel, Shirish M. Gadgeel, Carol O'Hear, Marcus Ballinger, Alan Sandler, Diego Cortinovis, Sylvia Hu, Catherine Lai, Lou Fehrenbacher, Jyoti D. Patel
Publikováno v:
Lung Cancer. 128:105-112
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods Patients received 1200 mg atezolizumab or 75
Autor:
Filippo de Marinis, Cesare Gridelli, Maria Chiara Garassino, Francesco Grossi, Antonio Rossi, Adolfo Favaretto, Editta Baldini, Maria Rita Migliorino, Paolo A. Ascierto, Alessandro Morabito
Publikováno v:
Current Clinical Pharmacology. 13:76-84
Background: Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approv
Autor:
Letizia Gianoncelli, Marcello Tiseo, Paolo Pedrazzoli, Antonio Maconi, Federico Cappuzzo, Stefano Frega, Maria Pagano, Giulia Pasello, Matteo Perrino, F. Zanelli, Maria Bonomi, Carmine Pinto, Filippo de Marinis, Luca Boni, Federica Grosso, Armando Santoro, Candida Bonelli, Marina Chiara Garassino, Paolo Andrea Zucali, Francesco Grossi, Giovanni Luca Ceresoli, Erika Gervasi, Hector Soto Parra
Summary Background There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab combined with gemcitabine in patients with pretreated malignant pleur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78597edc6a57d0d326a538c014d92e8a
http://hdl.handle.net/11383/2125715
http://hdl.handle.net/11383/2125715
Autor:
Letizia Gianoncelli, Antonio Passaro, Ilaria Attili, Chiara Catania, Giuseppe Curigliano, Valeria Stati, Stefania Morganti, Ester Del Signore, Gianluca Spitaleri, Filippo de Marinis
Publikováno v:
Cancer treatment reviews. 89
Immune checkpoint inhibitors (ICIs) represent one of the main steps forward for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC), without oncogenic driver alterations. Despite this recent progress, only a minority of patient
Autor:
Alberto Pavan, Filippo de Marinis, Laura Bonanno, Antonio Passaro, Ilaria Attili, Pierfranco Conte
Publikováno v:
Critical Reviews in Oncology/Hematology. 119:30-39
Immune checkpoint inhibitors (ICIs) have emerged as one of the main new therapeutic options for advanced non-small cell lung cancer (NSCLC) patients. Even though they demonstrated superiority towards standard chemotherapy in different disease setting